Table 1 Patients characteristics and main study results for AKT and MAPK immunohistochemistry in primary colorectal tumours

Age (range)

65 (36–80)

67 (41–80)

65 (36–78)

ns

65 (38–80)

66 (40–79)

ns

Sex

Males

51 (70%)

20 (65%)

31 (65%)

ns

23 (72%)

28 (70)

ns

Females

21 (30%)

11 (35%)

10 (35%)

ns

9 (28%)

12 (30%)

ns

ECOG PS

0–1

58 (81%)

27 (87%)

31 (76%)

ns

29 (90%)

29 (72%)

ns

2–3

14 (19%)

4 (13%)

10 (23%)

ns

3 (10%)

11 (28%)

ns

Metastatic sites

1

21 (30%)

8 (26%)

13 (32%)

ns

10 (32%)

11 (27%)

ns

≥ 2

51 (70%)

23 (74%)

28 (68%)

ns

22 (68%)

29 (73%)

ns

Previous lines of treatment

1

10 (14%)

4 (13%)

6 (15%)

ns

3 (9%)

7 (17%)

ns

≥ 2

62 (86%)

27 (87%)

35 (85%)

ns

29 (91%)

33 (83%)

ns

Treatment

mFOLFIRI + Cetuximab

28 (39%)

10 (32%)

18 (44%)

ns

12 (37%)

16 (40%)

ns

Irinotecan + Cetuximab

44 (61%)

21 (68%)

23 (56%)

ns

20 (63%)

24 (60%)

ns

Response Rate

PR

21 (29%)

5 (16%)

16 (39%)

ns

9 (28%)

12 (30%)

ns

SD

19 (26%)

8 (26%)

11 (27%)

ns

7 (22%)

9 (22%)

ns

PD

32 (45%)

18 (58%)

14 (34%)

ns

16 (50%)

19 (48%)

ns

Survival

m PFS (months)

3.2

2.4

6.5

0.0006

3

6

ns

m OS (months)

17.7

7.8

26.7

<0.0001

11.2

26.2

ns